Initial salvage treatment with allogenic stem cell transplant (ASCT) is feasible and yields superior outcomes to salvage chemotherapy in acute myeloid leukemia (AML) patients.
Adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab had a 72% response rate.
Afatinib significantly prolongs progression-free survival (PFS) among EGFR-mutation-positive lung cancer, compared to pemetrexed plus cisplatin.
Taxane-based chemotherapy plus lapatinib is associated with a shorter progression-free survival (PFS) than when combined with trastuzumab as first-line treatment for patients with HER2+ metastatic breast cancer.
Dexamethasone is more effective than placebo in reducing cancer-related fatigue (CRF) in patients with advanced cancer.
Biochemotherapy (BCT) demonstrates greater improvement in relapse-free survival (RFS) compared to high-dose interferon (HDI).
Vemurafenib improved overall survival (OS) in patients with BRAF600E-mutated metastatic melanoma.
Systemic corticosteroids resolve immune-mediated adverse reactions associated with ipilimumab treatment.
Dose-dense oxaliplatin therapy followed by an irinotecan-based regimen does not improve outcomes over standard FOLFOX4 chemotherapy for metastatic colorectal cancer patients.
In women with platinum-resistant ovarian cancer, bevacizumab plus chemotherapy doubled progression-free survival (PFS) compared with chemotherapy alone.
Please login or register first to view this content.
